There is no benefit in using a combination of AstraZeneca PLC’s investigational oral VEGF receptor tyrosine kinase inhibitor, Recentin (cedirinib), and AZ/Merck & Co. Inc.’s PARP inhibitor Lynparza (olaparib) over platinum-based chemotherapy to treat patients with platinum-sensitive relapsed ovarian cancer, top-line data from the Phase III GY004 study show. The results are another disappointment for Recentin, but they should do little to dent Lynparza’s dominance of the ovarian cancer PARP inhibitor market.
The GY004 trial, led by NRG Oncology and sponsored by the US National Cancer Institute (NCI), saw no improvement in...